Source: BMC Cancer  |  Posted 8 years ago

High-dose methotrexate produces modest toxicity and a radiographic response proportion of 74% among patients with primary central nervous system lymphomas. say researchers.

These findings are reported by Dr T Batchelor and colleagues from Massachusetts General Hospital, Boston, United States, as a result of a multi-centre, phase II study of single-agent, intravenous methotrexate among patients with newly diagnosed non-AIDS-related primary CNS lymphoma in the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium.

Twenty five patients, mean age 60 years, were given methotrexate at 8 g/m